Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

New guidelines on the safe use of analgesia in horses
Animal welfare can be significantly affected by pain.
Recommendations aimed at equine primary care in an ambulatory setting

Clinical guidelines for primary care vets on the safe use of analgesia in horses have been published in the January issue of the Equine Veterinary Journal (EVJ).

The guidelines have been produced by the British Equine Veterinary Association (BEVA) and can be downloaded at https://beva.onlinelibrary.wiley.com/doi/10.1111/evj.13198

In human medicine, clinical guidelines are standard practice and have proven to influence clinical decision making in clinical settings. BEVA’s set of clinical guidelines are the first to be aimed at equine primary care in an ambulatory setting.

Animal wefare can be significantly affected by pain and analgesia is considered to be key in helping to alleviate it. Put together by a panel combining clinicians and analgesia researchers, the guidelines summarise current evidence and combine it with expert opinion to provide best practice advice on common scenarios.

Key recommendations include:
  • Horses undergoing routine castration should receive intratesticular local anaesthesia irrespective of methods adopted and horses should receive NSAIDs before surgery. Butorphanol and buprenorphine should not be considered appropriate as sole analgesics for such procedures and analgesia should be continued for three days following castration.
  • For hoof pain/laminitis phenylbutazone provided superior analgesia to meloxicam and firocoxib but enhanced efficacy has not been demonstrated for joint pain.
  • In horses with colic, flunixin and firocoxib are considered to provide more effective analgesia than meloxicam or phenylbutazone.
  • A single properly validated composite pain score for horses should be developed, to allow accurate comparisons between medications in a robust manner.
“Given the risk of adverse events of all classes of analgesic, these agents should be used only under the control of a veterinary surgeon,” explained Professor Mark Bowen, lead author of the guidelines. “The horse must have been fully evaluated and the vet must have devised a therapeutic, analgesic plan that includes ongoing monitoring for such adverse events such as the development of right dorsal colitis with all classes of NSAID and spontaneous locomotor activity and potentially ileus with opiates.”

EVJ editor Professor Celia Marr added: “The BEVA primary care clinical guidelines provide up-to-date clarity on the fundamental aspects of equine pain management for the clinician and are essential reading for all those in first opinion ambulatory roles.”

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.